Immunosuppressive treatment protects against angiotensin II-induced renal damage - Wikidata - awgldk - TriplyDB

Immunosuppressive treatment protects against angiotensin II-induced renal damage

Immunosuppressive treatment protects against angiotensin II-induced renal damage

http://www.wikidata.org/entity/Q35747734

about

Recent advances in central cardiovascular control: sex, ROS, gas and inflammation Dendritic Cells and Their Role in Cardiovascular Diseases: A View on Human Studies Infiltrating immune cells in the kidney in salt-sensitive hypertension and renal injury Inflammation, immunity, and hypertensive end-organ damage Angiotensin II in inflammation, immunity and rheumatoid arthritis An update on immune system activation in the pathogenesis of hypertension The inextricable role of the kidney in hypertension Determination of an angiotensin II-regulated proteome in primary human kidney cells by stable isotope labeling of amino acids in cell culture (SILAC)Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension Tumor necrosis factor-α produced in the kidney contributes to angiotensin II-dependent hypertension.Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet Aggravated renal inflammatory responses in TRPV1 gene knockout mice subjected to DOCA-salt hypertension.TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats.Soluble TNF receptors and kidney dysfunction in the elderly.Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies.T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats.Classical Renin-Angiotensin system in kidney physiology Recent advances involving the renin-angiotensin system TNFR1-deficient mice display altered blood pressure and renal responses to ANG II infusion.Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase.Inflammation, immunity, and hypertension.An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension The immunological basis of hypertension High dietary protein exacerbates hypertension and renal damage in Dahl SS rats by increasing infiltrating immune cells in the kidney.Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease Inhibition of TNF in the brain reverses alterations in RAS components and attenuates angiotensin II-induced hypertension Immunoglobulin locus associates with serum IgG levels and albuminuria.Autoimmunity: an underlying factor in the pathogenesis of hypertension.Relaxin does not improve Angiotensin II-induced target-organ damage.Role of T lymphocytes in hypertension.Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosis Role of T lymphocytes in angiotensin II-mediated microvascular thrombosis Lymphocyte responses exacerbate angiotensin II-dependent hypertension.Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all.Statin, calcium channel blocker and Beta blocker therapy may decrease the incidence of tuberculosis infection in elderly Taiwanese patients with type 2 diabetes Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways.Eicosanoids and tumor necrosis factor-alpha in the kidney.Protective effect of TRPV1 against renal fibrosis via inhibition of TGF-β/Smad signaling in DOCA-salt hypertension.

P2860

Q26752442-B11049A5-4842-4493-9B49-7B079DBD7094 Q26752811-AC131C29-9596-49AD-8A56-81B06115A746 Q26822514-22FDBE75-0333-4221-ACA4-7EE1907AF80B Q26827525-7F71B048-848D-4271-A9A9-0DCF3D3A03B5 Q26991828-A277693D-AC1D-4006-8660-578C087C0F77 Q27013715-5A1E0AC4-1FDC-4180-9614-4EC00D9FB2B1 Q28241252-07B26D97-3BE7-4BB1-9AAF-06ABDF4F0122 Q28387627-7C70D407-1300-4FC0-925C-720ED3B86E36 Q28390972-43AEE488-2B2A-4CD0-9192-D9D0193A9580 Q30365965-5762DEDF-5DCD-451E-A8FA-444983952BD2 Q30482887-B3C1C63E-5E59-4FB9-B0AF-6EF1B80CA093 Q33570102-916D8227-B80C-42D0-BF73-7D0253795F4A Q33647618-1074ED4F-D94C-48A5-A5D8-916A48D504DB Q33660677-BDC405B5-9AF9-4920-BBA9-0206455B9FD6 Q33711255-F25DB57E-E396-469B-BEBE-942E1ADD4CB1 Q33784344-E16C8FE8-4F78-426C-BEC6-65E501696565 Q34065655-904D8994-D7E8-47E7-BA2D-A3DF67C6AA53 Q34260674-A9B240F2-CACE-41E8-942B-3186B2C03ABD Q34305595-FD8F755C-BA4A-4CCA-A33C-0DF0A1A6757E Q34339359-AE91AE89-4DB4-4228-AB48-BC70D22AC87C Q34442004-151CCE91-D525-418A-8E67-0BD4F718433F Q34457205-97023C69-0B43-4C7A-8752-090701D79EFD Q34528283-EE6267C2-BF23-4BB3-BD48-61920D1C8767 Q34557130-F61CAE2B-83C1-47A6-9270-EE2467D1E514 Q34683745-989535A6-C06C-4E9F-ADED-04F2525C2AAE Q34692169-EB0CFEF9-3A80-4E63-A58F-8D8935C56EBE Q34719254-B706ADEC-C20F-4FFF-BCD3-85569BD6FE41 Q34731058-A7F8BEA1-756E-45F6-8F9A-F2BD1D7A0290 Q34870753-F31E383C-BCBA-4DFF-A34A-3200334DB740 Q35116086-40B17708-3B97-4029-887C-80F8D24F7862 Q35141812-B746E939-CD52-4479-AD85-64E4DD49BE3E Q35236265-A9F7B209-AF31-4CF5-A30A-AF69F83514D7 Q35276739-19AD7175-44FD-4CD1-A515-8D4A6FE1B4C8 Q35421048-0B59B76B-A583-4318-83F0-B742373D573A Q35576468-60491063-D4D1-459A-904A-4B1A755E5495 Q35682855-D8B8D414-9969-466C-B651-1B5BFCA0FC6A Q35723779-82D56954-0ED4-4654-B5E2-18A2F5EBEDBD Q35791591-BF5F640B-C9CC-44F9-8F3B-F258B0BE3C47 Q35803739-7DD175B3-09C6-4504-8F4C-3E2D0DA06C7F Q35876750-F7D69F11-FA42-49C5-8CFC-22446DB7D912

P2860

Immunosuppressive treatment protects against angiotensin II-induced renal damage

http://www.wikidata.org/entity/Q35747734

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Immunosuppressive treatment protects against angiotensin II-induced renal damage

@ast

Immunosuppressive treatment protects against angiotensin II-induced renal damage

@en

type

label

Immunosuppressive treatment protects against angiotensin II-induced renal damage

@ast

Immunosuppressive treatment protects against angiotensin II-induced renal damage

@en

prefLabel

Immunosuppressive treatment protects against angiotensin II-induced renal damage

@ast

Immunosuppressive treatment protects against angiotensin II-induced renal damage

@en

P1433

Q35747734-65C686DC-F77A-4B76-A37C-58F32ABB903B

P1476

Q35747734-94BBE211-3086-4CCD-9EBB-6085C35E0777

P2093

Q35747734-2636D264-DB45-4007-BE0F-4440B23D2A82

Q35747734-2F6C0653-319C-4900-A1C8-A211E898E5FA

Q35747734-3DA60876-71B3-4EEC-B692-9DB191E5EA22

Q35747734-503C6CA4-BA20-41B4-A426-519EC995642F

Q35747734-64E6D29F-B174-413D-9326-7777784D0C29

Q35747734-688B214E-EB1C-424E-8C18-B0D4264C67E3

Q35747734-7F36F1ED-2C34-44D7-A742-3CC62E23034C

Q35747734-842578D3-8ED9-414A-BB79-EBE8EC300064

Q35747734-CCEEDC29-6C3E-4C1E-92D2-0F01912F157A

Q35747734-FBEBECE7-FADA-45EE-825C-BBDBDC6B5A61

P2860

Q35747734-05B9B5C5-5E7C-4C4B-81E6-A4BA477AFFBE

Q35747734-11C2FE08-DF86-49D6-ABCF-7C3E6702913D

Q35747734-19300D38-9630-48DD-91AE-B04319997BEB

Q35747734-307D295C-4D30-4581-8334-EC42E783EB6E

Q35747734-3AC215E2-F95D-4E89-BB28-6838F8A56840

Q35747734-5618ED52-B522-4697-B24E-156A33677E1E

Q35747734-5ECD1967-E4CD-48AE-A34F-F3F335BE43E1

Q35747734-62868507-A4FC-4DE8-AE15-42681D7DE256

Q35747734-6753D383-F059-4127-A4F5-AFBED03D02D8

Q35747734-68E90CF8-13B2-48B2-82A3-01BAAFE02886

P304

Q35747734-CF0D35AF-B2D5-4F2F-963C-45BDEEE0C0B4

P31

Q35747734-FD5D12E2-F7AB-413B-9DD6-D75B57CA6D75

P356

Q35747734-29209785-2005-4786-86BB-176C88BA7180

P407

Q35747734-1A8E9822-3CC9-4289-B2FD-07FE641C4940

P433

Q35747734-E12B2116-103F-4FF2-9B8C-A390190D746F

P478

Q35747734-BA34B203-C578-4724-BBB4-5A90C87831EE

P50

Q35747734-1D0D1630-9046-4BCE-9362-E00F4AE7F888

Q35747734-4DDB6E9E-8068-4FBA-83D8-1C96DC52AFFA

Q35747734-BF091939-BD2B-4DFF-B8E1-7566A17AEDCE

Q35747734-DA7AE016-59EE-4D0C-9FEA-1D09C4183F12

Q35747734-E6F8FDBD-31B4-45C5-9496-F45822CB5091

Q35747734-F97518AF-ECCA-413B-9AF2-C942460123BD

P577

Q35747734-DB496C5A-FC1B-4425-9C2A-717E732EB616

P698

Q35747734-39C7F1E5-4154-443A-B37B-1F1FF60BBF01

P932

Q35747734-60709C9C-424C-4182-8795-BE1833FF2870

P356

S0002-9440(10)64445-8

P1433

The American Journal of Pathology

P1476

Immunosuppressive treatment protects against angiotensin II-induced renal damage

@en

P2093

Christiane Viedt

http://www.w3.org/2001/XMLSchema#string

Eero Mervaala

http://www.w3.org/2001/XMLSchema#string

Franziska Hampich

http://www.w3.org/2001/XMLSchema#string

Harald Heidecke

http://www.w3.org/2001/XMLSchema#string

Joerg Kreuzer

http://www.w3.org/2001/XMLSchema#string

Joon-Keun Park

http://www.w3.org/2001/XMLSchema#string

Jürgen Theuer

http://www.w3.org/2001/XMLSchema#string

Martin Zenke

http://www.w3.org/2001/XMLSchema#string

Piet Finckenberg

http://www.w3.org/2001/XMLSchema#string

Xinsheng Ju

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells

Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes.

Is NF-kappaB the sensor of oxidative stress?

Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor.

Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.

The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease.

Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor.

Role of immunocompetent cells in nonimmune renal diseases.

Role of the renin-angiotensin system in vascular diseases: expanding the field.

P304

1679-1693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0002-9440(10)64445-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

161

http://www.w3.org/2001/XMLSchema#string

P50

Friedrich C. Luft

Dominik N. Muller

Anette Fiebeler

Erdenechimeg Shagdarsuren

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12414515

http://www.w3.org/2001/XMLSchema#string

P932

1850776

http://www.w3.org/2001/XMLSchema#string